Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BX Other blood glucose lowering drugs, excl. insulins
A10BX03 Nateglinide
D01111 Nateglinide (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Glucose Control Agents, Other
Nateglinide
D01111 Nateglinide (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D01111 Nateglinide (JP18/USP/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG01508 Sulfonylurea receptor agonist
DG01735 Glinide
D01111 Nateglinide
DG02044 Hypoglycemic agent
DG01735 Glinide
D01111 Nateglinide
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
D01111 Nateglinide
Drug classes [BR:br08332]
Antidiabetic agent
DG01735 Glinide
D01111 Nateglinide
DG02044 Hypoglycemic agent
D01111 Nateglinide
Target-based classification of drugs [BR:br08310]
Transporters
ABC transporters
ABCC subfamily
ABCC8(SUR1)/KCNJ11(KIR6.2)
D01111 Nateglinide (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01111 Nateglinide
D01111 Nateglinide tablets
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01111
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01111
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01111
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01111
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D01111